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Abstract 64 
Purpose: Mutations in the mitochondrial enzyme succinate dehydrogenase (SDH) subunit 65 
genes are associated with a wide spectrum of tumours including phaeochromocytoma and 66 
paraganglioma (PPGL) 1, 2, gastrointestinal stromal tumours (GIST) 3, renal cell carcinoma 67 
(RCC) 4 and pituitary adenomas5. SDH-related tumorigenesis is believed to be secondary to 68 
accumulation of the oncometabolite succinate. Our aim was to investigate the potential 69 
clinical applications of MRI spectroscopy (1H-MRS) in a range of suspected SDH-related 70 
tumours. 71 
Patients and methods: Fifteen patients were recruited to this study. Respiratory-gated single-72 
voxel 1H-MRS was performed at 3T to quantify the content of succinate at 2.4 ppm and 73 
choline at 3.22 ppm.  74 
Results: A succinate peak was seen in six patients, all of whom had a germline SDHx 75 
mutation or loss of SDHB by immunohistochemistry. A succinate peak was also detected in 76 
two patients with a metastatic wild-type GIST (wtGIST) and no detectable germline SDHx 77 
mutation but a somatic epimutation in SDHC. Three patients without a tumour succinate peak 78 
retained SDHB expression, consistent with SDH functionality. In six cases with a borderline 79 
or absent peak, technical difficulties such as motion artefact rendered 1H-MRS difficult to 80 
interpret. Sequential imaging in a patient with a metastatic abdominal paraganglioma 81 
demonstrated loss of the succinate peak after four cycles of [177Lu]-DOTATATE, with a 82 
corresponding biochemical response in normetanephrine. 83 
Conclusions: This study has demonstrated the translation into clinical practice of in vivo 84 
metabolomic analysis using 1H-MRS in patients with SDH-deficient tumours. Potential 85 
applications include non-invasive diagnosis and disease stratification, as well as monitoring 86 
of tumour response to targeted treatments.  87 
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Introduction 88 
The succinate dehydrogenase (SDH) enzyme is composed of four subunits (A-D) and has a 89 
key role in the Krebs cycle and oxidative phosphorylation6. In the past two decades germline 90 
mutations in the genes encoding the four SDH subunits (SDHA/SDHB/SDHC/SDHD), 91 
collectively known as SDHx have emerged as an important cause of human neoplasia and a 92 
paradigm for the role of disordered cellular metabolism in oncogenesis 1-5, 7. SDHx mutations 93 
were described initially in association with head and neck paragangliomas (derived from 94 
parasympathetic ganglia) and in phaeochromocytomas and paragangliomas (PPGL, derived 95 
from sympathetic ganglia and often secreting catecholamines) 1, 2. It is now recognised that 96 
approximately 40% of PPGL patients harbour a germline mutation in an inherited PPGL gene 97 
and SDHx mutations are the most common cause of PPGL predisposition9. In addition, 98 
germline SDHB mutations are associated with a high risk of malignancy in PPGL9. Other 99 
tumour types associated with SDHx mutations include gastrointestinal stromal tumours 100 
(GISTs) and renal cell carcinomas (RCCs)10-13. GISTs are mesenchymal tumours of the 101 
gastrointestinal tract and in adults usually associated with somatic activating mutations in the 102 
KIT or PDGFRA genes3, 11. However GISTs without KIT and PDGFRA gene mutations3, 103 
known as wild-type (wtGIST), account for 15% of adult and 85% of paediatric GIST tumours 104 
and recent studies suggest that up to 88% of wtGIST are SDH-deficient11. wtGIST with 105 
SDH-deficiency may harbour a germline SDHx mutation (75% of cases) or an SDHC gene 106 
epimutation with hypermethylation of the promoter region11. Only about a third of patients 107 
with SDH-deficient wtGIST achieve disease stabilisation with imatinib therapy12 and the risk 108 
of metastatic disease is higher for SDH-deficient GIST compared to conventional GIST11, 12. 109 
SDHx-associated RCC may present in patients with a personal or family history of PPGL or 110 
may present with an RCC-only phenotype13. Finally germline SDHx mutations have been 111 
described in rare patients with pituitary adenomas10. Despite recent advances in the 112 
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understanding of the SDHx genes, there are many areas of unmet clinical need including a 113 
lack of robust biomarkers to predict aggressive biological behaviour and to inform on clinical 114 
surveillance and management14.  115 
Succinate has been shown to be elevated by 100-fold in SDHx-mutated PPGL tumours ex-116 
vivo compared with non-SDHx mutated PPGL tumours15. Recently, in vivo detection of 117 
succinate by MR spectroscopy was reported in two patient cohorts with SDH deficient 118 
PPGL16, 17. Similarly, the non-invasive detection of 2-hydroxyglutarate with 1H-MRS has 119 
been demonstrated in glioma in patients with a gain of function mutation in another citric 120 
acid cycle enzyme, isocitrate dehydrogenase 1 (IDH1)18. The ability to measure succinate in 121 
vivo has a number of important potential clinical applications including early identification of 122 
SDH deficiency, which can enable tailored patient surveillance and management. In vivo 123 
detection of succinate accumulation could also serve to verify genetic variant pathogenicity in 124 
the era of next generation sequencing. The aim of this study was to investigate the role of 1H-125 
MRS in detecting abnormally elevated succinate in vivo in patients with suspected SDH 126 
deficient tumours, expanding the applications of 1H-MRS in SDH deficient tumorigenesis to 127 
include GIST and pituitary adenoma for the first time and to explore the technique as a 128 
potential non-invasive biomarker of treatment response.  129 
 130 
Methods 131 
Patient selection 132 
This study was performed as a prospective case series and subjects were recruited from a 133 
dedicated neuroendocrine tumour clinic and a national paediatric and adult wild-type 134 
(PAWS) GIST clinic in Cambridge University NHS Foundation Trust. Suitable patients were 135 
identified based on SDHx germline status, suspicious clinical phenotype (metastatic PPGL, 136 
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paraganglioma or wtGIST) and/or immunohistochemistry of tumour tissue showing absent 137 
SDHB immunostaining. A minimum tumour size threshold of 1.5cm was applied for 138 
inclusion into the study. All participants gave written informed consent and the study was 139 
approved by Cambridge South Research Ethics Committee.  140 
 141 
MRS Analysis  142 
Both SAGE (GE Healthcare, Waukesha, WI) and LCModel19 spectroscopy analysis 143 
programmes were used to reconstruct, analyze and display spectra. For each metabolite, 144 
LCModel reports both peak area and the estimated uncertainty in fitting of the peak (%SD). 145 
This uncertainty measure was used to stratify the results using the following algorithm: 1) if 146 
%SD of choline was >15%, the spectrum was discarded as a technical failure, because it was 147 
assumed that choline should be detectable in a metabolically active tumour, such that 148 
SD>15% would indicate probable data quality issues; 2) succinate detection was taken as 149 
positive if its %SD was <50%, and negative if it was >50%. The succinate to choline ratio 150 
was quantified (SCR), the full width at half maximum height (FWHM) of the water peak in 151 
Hz was measured in SAGE and recorded as an additional data quality metric, and an expert 152 
spectroscopist was asked to rate whether detected succinate peaks were convincing or 153 
unconvincing based on data displayed both in LCModel and in SAGE. 154 
 155 
Statistical methods, 1H-MRS data acquisition,  Germline genetic analysis, SDHB 156 
Immunohistochemistry, SDHC hypermethylation analysis and measurement of succinate in ex  157 
vivo tissue samples 158 
See supplementary data. 159 
 160 
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Results 161 
Patients and clinical phenotype 162 
Fifteen subjects (6 females, 9 males; mean age 40 years (range 21-80 years) were studied. 163 
Seven wtGIST, three unilateral adrenal phaeochromocytomas, three abdominal PGL’s, a 164 
large left glomus PGL and a non-functioning pituitary macroadenoma were examined. Nine 165 
patients (60%) had metastatic disease: six with wtGIST, two with an abdominal 166 
paraganglioma and one with a unilateral phaeochromocytoma. The liver was the most 167 
common site for metastases (7/9, 77.7%). Three patients had multicentric primary tumours, 168 
including subject #5 who presented with a metastatic wtGIST and was subsequently 169 
diagnosed with a 1.9 cm carotid body PGL (figure 2d, case 5), subject #9 with an abdominal 170 
paraganglioma and a small left sided 1.5 cm carotid paraganglioma (figure 3b, case 9), and 171 
subject #8 with a large left sided glomus paraganglioma and a 2 cm prolactin secreting 172 
pituitary adenoma (figure S1, case 8). Only two patients had a positive family history, (Table 173 
1: case 2 and case 6). 174 
Genotype 175 
A germline mutation in a SDHx gene was identified in 9/15 (60%) of subjects: 5 in SDHB (4 176 
missense variants and 1 truncating variant) and 4 in SDHA (1 missense and 3 truncating). 177 
Two further patients were diagnosed with a somatic SDHC epimutation (Table 1). 178 
 179 
1H-MRS succinate analysis  180 
The 1H-MRS characteristics of the 15 patients are shown in Supplementary Table S1. The 181 
mean size of the tumour selected for spectra acquisition was 5.5 cm (median: 3.3 cm, range: 182 
1.8-12 cm). The liver was the most common site to be assessed (n = 6), but good quality 183 
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spectra were also obtained from the pituitary (n = 1), and PPGL tumours (n = 5). The subjects 184 
were divided into four groups according to whether a succinate tumour peak was: present, 185 
absent, a borderline peak was detected, or technical failure prevented interpretation of the 186 
spectra. 187 
 188 
Succinate peak detected 189 
Succinate was detected at 2.4 ppm in 6 patients (50 %). The mean SCR in these patients was 190 
1.3 (SD  0.71) and the mean tumour size in those six patients with reliable succinate peak 191 
detection was 4.8 cm (SD  2.94, range 2.3-9 cm). The in vivo detection of succinate on 1H-192 
MRS correlated with tumour SDH deficiency: 4 of the 6 cases had a germline SDHx mutation 193 
and loss of SDHB expression on immunohistochemistry and a somatic SDHC epimutation 194 
was detected in 2 of the 6 (Figure 1). 195 
 196 
 197 
Borderline succinate peak detected 198 
A borderline succinate peak was detected in two subjects. Patient #8 with a germline SDHB 199 
mutation (c.600G>T p.Trp200Cys) and a glomus paraganglioma, demonstrated an SCR of 200 
1.19; however the linewidth (29 Hz) was so broad due to the proximity of metallic dental 201 
work that the peak assignments were not reliable (Figure S1). Patient #7 with a metastatic 202 
phaeochromocytoma and no detectable germline SDHx mutation demonstrated an SCR of 203 
0.18 but the LCModel detected a very small succinate peak at 2.4 ppm; this patient did not 204 
undergo surgery or a diagnostic biopsy and therefore no tissue was available for further 205 
analysis and therefore we have classified this case as borderline.  206 
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No succinate peak 207 
No succinate peak was detected in three subjects. Patient #4 had a metastatic wtGIST with no 208 
detectable germline SDHx mutation and preserved SDHB protein expression in the tumour 209 
tissue; choline was confidently fitted on LCModel but no succinate was seen. Patient #6 210 
demonstrated a good quality spectrum from the remnant pituitary adenoma; choline was 211 
detected on LCModel and SAGE processing but no succinate was detected and this finding 212 
was consistent with the preservation of SDHB protein expression in the pituitary tumour by 213 
immunohistochemistry (Figure 4). Patient #10 had no detectable germline SDHx mutation 214 
and preserved SDHB protein expression in the tumour tissue; choline was detected in the 215 
tumour on 1H-MRS but succinate was not detected. 216 
 217 
 218 
Technical failure 219 
Technical failure occurred in four patients (26%). Patient #12 demonstrated no reliable 220 
detection of succinate or choline due to motion artefact and a low signal-to-noise ratio (SNR), 221 
which was probably due to inconsistent breathing as the voxel was at the edge of the liver. A 222 
small rib metastasis was imaged in patient #13 but only a pure lipid spectrum was obtained 223 
from this challenging location. A metastasis on the edge of the liver was imaged in patient 224 
#14, where again inconsistent respiration probably led to displacement of the voxel into 225 
adjacent adipose tissue. Finally, patient #15 had a unilateral phaeochromocytoma with a large 226 
volume of blood, whose paramagnetic properties may have affected acquisition leading to 227 
low SNR (Supplementary Table S1). 228 
 229 
Sequential 1H-MRS succinate analysis  230 
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Subject #2 with a metastatic paraganglioma to the lung, bone and lymph node and a germline 231 
SDHB mutation (c.268C>T p.Arg90*) underwent 1H-MRS on a large pelvic nodal metastasis 232 
prior to treatment with four cycles of lutetium 177-labelled peptide receptor radionuclide 233 
therapy. Succinate and choline peaks were detected with an SCR of 1.32 (Figures 5a, 5b). 234 
Following four cycles of treatment, a repeat 1H-MRS examination on the same pelvic nodal 235 
metastases revealed a choline peak but no succinate peak (Figure 5c). Though the MRI 236 
imaging features of the metastatic lesions were unchanged pre- and post-treatment, the loss of 237 
a succinate peak was correlated with a reduction in plasma normetanephrine levels (from 238 
1861 to 1193 pmol/L) and tumour avidity on 18F-fluorodeoxyglucose Positron Emission 239 
Tomography/Computed Tomography (FDG-PET/CT; standard uptake value of 16.1 pre-240 
treatment and 9.3 post-treatment; Figure 5d-f). The detection of choline on the acquired 241 
spectra both before and after treatment indicates that tumour necrosis is unlikely to account 242 
for the absent succinate peak post treatment.  243 
A sequential 1H-MRS study was performed on patient #5 due to evidence of progressive 244 
disease on surveillance CT, despite treatment with a multi-kinase inhibitor, regorafenib. 245 
Serial 1H-MRS demonstrated a larger succinate peak compared to the first study (Figure 2d 246 
and 2e) and this correlated with the FDG avidity on PET/CT pre-treatment and ten months 247 
post-treatment, which demonstrated an increase in disease burden and avidity (SUV: 15.1 and 248 
27.1 respectively, Figures 2f-g).  249 
Repeatability of 1H-MRS was evaluated in two patients by investigating different tumour 250 
deposits during the same study examination (case#5) and the same tumour deposit twice 251 
during the same study examination (case#1). The results for succinate: choline were almost 252 
identical in these two cases, suggesting good test reproducibility (Supplementary Table 2) 253 
 254 
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Discussion 255 
This proof-of-principle study has demonstrated that detection of a succinate peak and an 256 
increased succinate to choline ratio were specific for a variety of SDH-deficient tumour 257 
types. All six tumours with a positive succinate peak and elevated SCR were associated with 258 
a germline SDHx mutation (n = 4) or an SDHC epimutation (n = 2). In addition, the three 259 
subjects with absent succinate peaks but adequate 1H-MRS, demonstrated preservation of 260 
SDHB expression in the tumour analyzed. Our findings are complementary to a previous 261 
study in which 1H-MRS was applied to 9 patients with paraganglioma and a succinate peak 262 
was detected in all 5 with an SDHx mutation but not in the 4 patients without a mutation16. 263 
We have demonstrated for the first time that 1H-MRS can also be used to determine the SDH 264 
status of GISTs and pituitary adenomas and that a succinate peak can be detected in SDH-265 
deficient tumours with epigenetic inactivation of SDHC. There are a wide variety of 266 
situations in which 1H-MRS might have clinical utility. Potential diagnostic applications of 267 
this new approach include: (a) assessing the pathogenicity of patients with a germline SDHx 268 
variants of uncertain significance and a potentially SDH-related tumour; (b) investigating 269 
possible metastatic lesions e.g. in the liver, in patients with a germline SDHx mutation and a 270 
primary SDH-deficient tumour; (c) assessing patients with multiple primary tumours to 271 
determine if all are SDH-deficient; (d) identifying patients without a detectable germline 272 
SDHx mutation who might benefit from specialist genetic investigations such as SDHC 273 
promoter methylation status; and (e) assessing SDH tumour status pre-operatively 274 
particularly for patients with possible wtGIST as standard adjuvant treatment with imatinib 275 
has proven to be less effective in patients with SDH-deficient disease12.  276 
Notably, here we have used the presence of a choline signal as an internal control for viable 277 
tissue to discriminate technical failures from a negative finding. To avoid issues of partial 278 
voluming effects within smaller tumours, the voxel for MRS analysis was chosen to fully 279 
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include tumour where possible. We did not detect a statistically significant correlation 280 
between tumour size and succinate/choline ratio although there was a trend towards 281 
significance. This trend is the opposite of what would be expected if necrosis was artificially 282 
lowering the overall succinate levels in large tumours, and therefore suggests that the method 283 
is measuring real differences in succinate, which are independent of tumour size. However, 284 
we recommend using a size threshold of greater than 2 cm where possible to improve the 285 
sensitivity of the test.  286 
There is increasing interest in understanding the metabolic adaptations that occur during 287 
tumorigenesis and how these might be exploited for novel therapeutic interventions. 288 
Increased production of lactate during aerobic glycolysis in most cancers, or the Warburg 289 
effect, is the best known example of this. SDH-related cancers provides a paradigm for 290 
investigating tumour metabolism as succinate is thought to act as an oncometabolite and to 291 
drive tumorigenesis6. Succinate inhibits 2-oxoglutarate-dependent dioxygenases including 292 
DNA and histone demethylases and hypoxic gene response regulators. As a consequence, 293 
SDH-deficient tumours demonstrate epigenetic abnormalities, an activated hypoxic gene 294 
response and more recently there is evidence that succinate may have a paracrine effect on 295 
stromal tissue20, 21, 22. Understanding the molecular mechanisms of SDH-related 296 
tumorigenesis provides a rationale for novel therapeutic interventions such as reversing the 297 
epigenetic abnormalities or exploiting metabolic vulnerabilities, similar to the recent 298 
discovery that tumoral 2-hydroxyglutarate accumulation may increase responsiveness to 299 
olaparib, a poly-ADP-ribose polymerase (PARP) inhibitor23. The availability of sensitive 300 
non-invasive biomarkers would greatly facilitate precision medicine-based clinical trials. 301 
Imaging with 18F-FDG PET to measure the uptake and phosphorylation of a glucose-302 
analogue to probe the increased glucose utilisation that occurs in many metabolically-active 303 
cancers, is a useful form of in vivo metabolic imaging and has been employed for the 304 
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detection of primary and metastatic disease in many tumour types including PPGL and 305 
GIST24, 25 and is in widespread clinical use. However, despite being a very sensitive imaging 306 
tool, 18F-FDG PET lacks specificity and cannot differentiate individual metabolites. 1H-MRS 307 
is highly specific and allows in vivo detection of individual metabolites without the use of 308 
ionising radiation, however, 1H-MRS is significantly less sensitive than PET, which could 309 
limit the detection of low levels of succinate and it can be challenging to differentiate 310 
intracellular from extracellular metabolites. In the future, 1H-MRS may be complemented by 311 
other techniques such as hyperpolarised 13C-MR spectroscopic imaging, which can increase 312 
MR signal-to-noise by several orders of magnitude allowing assessment of enzyme flux in 313 
vivo26.  314 
 315 
We have shown that 1H-MRS could be a valuable tool for the assessment of tumour response 316 
in the context of radionuclide and other therapies as alterations in succinate levels were 317 
detected despite stable appearances of the tumour diameter. This important application of 1H-318 
MRS could be expanded to include other tumours with specific metabolic defects including 319 
fumarate hydratase deficient tumours27, IDH1 mutant tumours28 and the recently identified 320 
malate dehydrogenase 2 (MDH2) deficient tumours29. However, important limitations of in 321 
vivo metabolomic analysis using 1H-MRS were also revealed by our study: for example, 322 
spectral quality was poor in close proximity to metal dental work, adjacent to air spaces 323 
including the lung, in bone metastases, and was susceptible to motion artefact. In this study, 324 
the technical failure rate was 26%, which is similar to the failure rate reported in previous 325 
studies using 1H-MRS16. Importantly, no cases was excluded from this prospective study, 326 
with the intention that this would inform on the translation of this imaging modality into 327 
clinical practice. Based on the evidence from this exploratory study, we would recommend 328 
that tumours were selected for 1H-MRS analysis based on: (i) ideally the largest tumour 329 
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deposit but at least a size greater than 2 cm, (ii) tumours located close to bone or lung should 330 
be avoided, (iii) tumours with significant necrosis or hemorrhage should be avoided, (iv) 331 
superficial tumour deposits should be selected preferentially, and (v) respiratory triggered 332 
acquisition should be used for tumours in the upper abdomen, such as hepatic metastases. 333 
Although the use of 1H-MRS as a diagnostic tool is likely to be limited to specialist centres, 334 
the number of scan averages in our study during spectral acquisition was less than half those 335 
reported in a previous study16 (200 versus 512), without demonstrating a reduction in 336 
sensitivity. Using fewer scan averages reduces the acquisition time, making it more cost 337 
effective and convenient for the patient. This is a particularly important consideration if this 338 
imaging technique is to be considered for routine clinical practice or for sequential follow-up 339 
as part of a clinical trial. Furthermore this imaging modality could be used to investigate 340 
other metabolically-driven tumours. 341 
 342 
In conclusion, this study is the largest to date to evaluate 1H-MRS in patients with SDH 343 
deficiency. It has revealed that 1H-MRS has the potential to be used as a non-invasive 344 
biomarker in the precision management of SDH-deficient disease and could have a role as a 345 
biomarker of successful treatment response. Lessons learned from this study could be applied 346 
to other similar metabolically-driven tumours. 347 
 348 
 349 
 350 
 351 
 352 
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Tables: 464 
Table 1: Clinical characteristics of the cohort. PA = pituitary adenoma, PC = 465 
phaeochromocytoma. 466 
Case 
number 
Genetic 
mutation 
Sex Age Primary 
tumour 
Metastatic 
disease  
Site of 
metastatic 
disease 
Family 
history 
Other 
primary 
tumour 
1 SDHC 
epimutation 
F 21 GIST Yes Liver, 
lung 
No No 
2 SDHB  
c.268C>T 
p.(Arg90* ) 
F 53 Abdomin
al PGL 
Yes Lymph 
nodes, 
bone 
Yes- 
mother 
(GIST) 
No 
3 SDHC 
epimutation 
F 25 GIST Yes Liver No No 
4 No mutation 
detected 
F 27 GIST No NA No No 
5 SDHB 
c.137G>A 
p.(Arg46Gln) 
M 38 GIST Yes Liver, 
peritoneu
m 
No No 
6 SDHB 
c.380G>T 
p.(Ille127Ser) 
M 80 PA No NA Yes 
nephew 
(PPGL) 
No 
7 No mutation 
detected 
M 70 PC Yes Liver, 
bone 
No No 
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8 SDHB  
c.600G>T 
p.(Trp200Cys) 
M 41 Glomus 
PGL 
No NA No Yes, PA 
9. SDHB 
c.302G>A 
p.(Cys101Tyr) 
M 26 Abdomin
al PGL 
No NA No Carotid 
PGL 
10. No mutation 
detected 
M 23 PC No NA No No 
11. SDHA  
c.91C>T 
p.(Arg31Ter) 
F 21 GIST Yes Liver No No 
12. SDHA 
c.1765C>T 
p.(Arg589Trp) 
F 37 GIST Yes Liver No No 
13 SDHA  
c.91C>T 
p.(Arg31Ter) 
M 46 PGL Yes Bone No No 
14 SDHA  
c.91C>T 
p.(Arg31Ter) 
M 24 GIST Yes Liver No No 
15 No mutation M 67 PC No NA No No 
 467 
Figure legends 468 
Figure 1. (A): T2-weighted MR image from case 1 and (B) T1-weighted image from case 3 469 
demonstrating liver metastases from which spectra were acquired in the locations indicated 470 
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by the white arrows. (C-D) show the spectra from case 1 and case 3 demonstrating a 471 
succinate peak at 2.4 ppm. (E-F) demonstrate hypermethylation of the promoter region of the 472 
SDHC gene in tumour DNA from cases 1 and 3, confirming a somatic SDHC epimutation: 473 
55% mean methylation in case 1 and 75% mean methylation in case 3. 474 
 475 
 476 
Figure 2. (A) T1-weighted MR image of a metastatic GIST to the liver (arrow) from case 5. 477 
(B) SDHB immunonegativity on SDHB immunohistochemistry performed on the wt GIST 478 
tumour from the same patient. (C) Axial fused 18F-FDG PET/CT image demonstrating an 479 
FDG-avid carotid body PGL after SDH deficiency was demonstrated on 1H-MRS. (D-E) 480 
Spectra acquired at 1H-MRS from the same case before and during treatment with a multi-481 
kinase inhibitor. (F-G) Axial fused 18F-FDG PET/CT images and corresponding coronal PET 482 
projections illustrating the increase in disease burden and FDG avidity over time (SUV: 15.1 483 
and 27.1) which correlates with the increase in the succinate peak demonstrated on 1H-MRS.  484 
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 485 
 486 
Figure 3. (A) T2-weighted MRI showing a large non-secretory abdominal paraganglioma 487 
from case 9 (arrow). (B) 1H-MR spectra demonstrating a succinate peak at 2.4 ppm. (C) Axial 488 
fused 18F-FDG PET/CT image. The corresponding coronal maximum intensity projection 489 
(MIP) PET image demonstrates a synchronous left sided carotid paraganglioma. (D) Spectra 490 
acquired by High Resolution Magic Angle Spinning (HR-MAS) in vitro on the 491 
paraganglioma tumour sample, again confirming a succinate peak at 2.4 ppm. 492 
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 493 
 494 
Figure 4: (A) Coronal T1-weighted MRI demonstrating a remnant pituitary adenoma in case 495 
6 (white arrow). (B) Spectra acquired from the pituitary tumour at 1H-MRS, with evidence of 496 
choline detection but no succinate. (C) SDHB IHC demonstrating preservation of the SDHB 497 
protein performed on a section of tumour tissue debulked from the pituitary tumour. 498 
 499 
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Figure 5. (A) Axial T2-weighted MRI image of a retroperitoneal nodal metastases from case 2 500 
(arrow). (B) Spectra acquired before treatment illustrating succinate accumulation at 2.4 ppm. 501 
(C) Spectra acquired following 4 cycles of [177Lu]-DOTATATE with no detectable succinate 502 
peak at 2.4 ppm. (D) Plasma metanephrine and methoxytyramine levels before and after 503 
treatment with [177Lu]-DOTATATE. (E) Axial fused 18F-FDG PET/CT image and 504 
corresponding coronal PET projection showing the FDG-avid nodal metastases (SUV = 16.1, 505 
arrowed). (F) The same nodal metastases following treatment with [177Lu]-DOTATATE 506 
demonstrating reduced tracer uptake in keeping with the biochemical findings (SUV = 9.3). 507 
  508 
 509 
 510 
 511 
 512 
 513 
 514 
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Supplementary data: 515 
Figure S1: (A) Coronal MRI image of a large left sided glomus paraganglioma from case 8 516 
demonstrated by the white arrow. (B) Spectra processed with LCModel from the same patient 517 
showing a broad unreliable peak at 2.4 ppm, which was not convincing for succinate. 518 
Table S1: Characteristics of the 15 tumours analysed by 1H-MRS. TF: technical failure, 519 
defined as an estimated uncertainty (%SD) > 15% in automated peak fitting of choline using 520 
LCModel. ND: not detected. NA: not applicable. 521 
Table S2: Characteristics of the two patients in whom 1H-MRS was repeated during the same 522 
examination to evaluate test reproducibility. 523 
 524 
